Sino Biopharmaceutical Ltd (HK:1177)
:1177
Want to see HK:1177 full AI Analyst Report?
1177 Stock Chart & Stats
HK$6.00
-HK$0.02(-0.67%)
At close: 4:00 PM EST
HK$6.00
-HK$0.02(-0.67%)
Day’s Range― - ―
52-Week RangeHK$4.42 - HK$9.12
Previous CloseN/A
Volume63.93M
Average Volume (3M)114.93M
Market Cap
HK$83.08B
Enterprise ValueHK$85.73B
Total Cash (Recent Filing)HK$19.82B
Total Debt (Recent Filing)HK$11.96B
Price to Earnings (P/E)30.9
Beta0.88
Next Earnings
Aug 26, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield1.4%
Share Statistics
EPS (TTM)0.20
Shares Outstanding18,705,018,000
10 Day Avg. Volume98,005,928
30 Day Avg. Volume114,926,811
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.44Price Target Upside40.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.23
Revenue Forecast (FY)HK$35.91B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 78%–83% indicate durable product-level profitability and pricing power in specialty pharmaceuticals. This margin profile supports healthy contribution to operating earnings, enables R&D reinvestment and commercial spending, and cushions volatility in SG&A or reimbursement shifts over months.
Re-accelerating RevenueTop-line momentum re-accelerating signals improving product uptake or successful launches, increasing scale across hospital and retail channels. Sustained revenue growth improves operating leverage, spreads fixed costs, and supports long-term investment in pipeline and commercial expansion over the coming 2–6 months.
Strong Cash GenerationHealthy free cash flow and a FCF-to-net-income ratio ~0.82 show solid cash conversion and earnings quality. Reliable cash generation underpins funding for R&D, capex and debt servicing without immediate equity raises, supporting durable operational flexibility and strategic initiatives over the medium term.
Bears Say
Declining Net MarginA material drop in net margin reduces retained earnings available for reinvestment and weakens earnings durability. If bottom-line pressure persists, it can constrain R&D and commercialization budgets, and magnify earnings volatility across reporting periods, increasing execution risk over the medium term.
Rising LeverageMeaningful increase in leverage weakens financial flexibility and raises interest and refinancing risk, especially amid falling net margins. Higher leverage narrows the company’s ability to fund acquisitions or cushion revenue shortfalls, making capital allocation more constrained over the next several quarters.
Modest Cash Coverage Vs ProfitA low coverage ratio (~0.37) implies operating profit does not reliably convert to cash, exposing the company to working-capital swings and non-cash adjustments. This makes near-term cash available for operations and investments more sensitive to receivables, inventory and one-off items.
Sino Biopharmaceutical News
1177 FAQ
What was Sino Biopharmaceutical Ltd’s price range in the past 12 months?
Sino Biopharmaceutical Ltd lowest stock price was HK$4.42 and its highest was HK$9.12 in the past 12 months.
What is Sino Biopharmaceutical Ltd’s market cap?
Sino Biopharmaceutical Ltd’s market cap is HK$83.08B.
When is Sino Biopharmaceutical Ltd’s upcoming earnings report date?
Sino Biopharmaceutical Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 80 days.
How were Sino Biopharmaceutical Ltd’s earnings last quarter?
Sino Biopharmaceutical Ltd released its earnings results on Mar 26, 2026. The company reported HK$0.011 earnings per share for the quarter, missing the consensus estimate of HK$0.069 by -HK$0.057.
Is Sino Biopharmaceutical Ltd overvalued?
According to Wall Street analysts Sino Biopharmaceutical Ltd’s price is currently Undervalued.
Does Sino Biopharmaceutical Ltd pay dividends?
Sino Biopharmaceutical Ltd pays a Quarterly dividend of HK$0.05 which represents an annual dividend yield of 1.4%. See more information on Sino Biopharmaceutical Ltd dividends here
What is Sino Biopharmaceutical Ltd’s EPS estimate?
Sino Biopharmaceutical Ltd’s EPS estimate is 0.14.
How many shares outstanding does Sino Biopharmaceutical Ltd have?
Sino Biopharmaceutical Ltd has 18,705,018,000 shares outstanding.
What happened to Sino Biopharmaceutical Ltd’s price movement after its last earnings report?
Sino Biopharmaceutical Ltd reported an EPS of HK$0.011 in its last earnings report, missing expectations of HK$0.069. Following the earnings report the stock price went down -1.855%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:1177
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sino Biopharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$8.44 (40.71% Upside)
HK$8.44 (40.71% Upside)
Insider Transactions
Bought Shares
Worth HK$68.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.30%
12-Months-Change
Fundamentals
Return on Equity
11.03%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
1177 Stock 12 Month Forecast
Average Price Target
HK$8.44
▲(40.71% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---